Company Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:06 2024-04-30 am EDT 5-day change 1st Jan Change
3.225 GBX -9.15% Intraday chart for Fusion Antibodies plc -15.13% -24.12%

Business Summary

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

Number of employees: 48

Sales per Business

GBP in Million2022Weight2023Weight Delta
Recombinant Proteins and Antibodies
100.0 %
5 100.0 % 3 100.0 % -39.55%

Sales per region

GBP in Million2022Weight2023Weight Delta
North America
51.6 %
2 41.7 % 1 51.6 % -25.20%
United Kingdom
21.4 %
1 15.1 % 1 21.4 % -14.23%
Rest of Europe
14.1 %
1 29.0 % 0 14.1 % -70.66%
Rest of World
12.9 %
1 14.2 % 0 12.9 % -44.93%

Managers

Managers TitleAgeSince
Chief Executive Officer 57 22-08-14
Director of Finance/CFO 49 23-08-23
Chairman 65 05-12-31
Chief Operating Officer - 16-05-31
Chief Tech/Sci/R&D Officer 47 01-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 68 06-12-31
Chairman 65 05-12-31
Chief Tech/Sci/R&D Officer 47 01-12-31
Director/Board Member 53 22-02-28
Chief Executive Officer 57 22-08-14
Director/Board Member 53 15-12-31
Director of Finance/CFO 49 23-08-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 95,365,564 85,480,210 ( 89.63 %) 0 89.63 %

Shareholders

NameEquities%Valuation
Unicorn Asset Management Ltd.
6.708 %
6,397,290 6.708 % 303 040 p
Rathbones Investment Management Ltd.
4.732 %
4,513,062 4.732 % 213 784 p
Invest Northern Ireland
3.353 %
3,197,865 3.353 % 151 483 p
Amati Global Investors Ltd. (Venture Capital)
3.311 %
3,157,836 3.311 % 149 587 p
Clarendon Fund Managers Ltd.
1.921 %
1,831,500 1.921 % 86 758 p
Crescent Capital NI Ltd.
1.468 %
1,400,000 1.468 % 66 318 p
Gresham House Asset Management Ltd.
1.337 %
1,275,332 1.337 % 60 412 p
Octopus Investments Ltd.
1.330 %
1,267,954 1.330 % 60 063 p
905,175 0.9492 % 42 878 p
668,865 0.7014 % 31 684 p

Company contact information

Fusion Antibodies Plc

Springbank Industrial Estate 1 Springbank Road

BT17 0QL, Belfast

+44 28 9043 2800

http://www.fusionantibodies.com
address Fusion Antibodies plc(FAB)
  1. Stock Market
  2. Equities
  3. FAB Stock
  4. Company Fusion Antibodies plc